~~<i id='FFF3E1C5BB'><strike id='FFF3E1C5BB'><tt id='FFF3E1C5BB'><pre id='FFF3E1C5BB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：fashion 2025-09-28 15:56:49 - browse：39

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Doctors have an ethical obligation to be advocates

focus

leisure time

hotspot

entertainment

leisure time

focus

TheFDAhasapprovedadevicefromAbbottthatcontinuouslymonitorsdiabetics’bloodsugarlevelswithoutrequiring

WSS

Dana Farber says 6 studies to be retracted and 31 corrected

Flu vaccine reformulation won't be easy, manufacturers warn

Malaysia cuts short music fest after British band slams anti

Microsoft launches AI tool for clinical documentation through Epic

High breast density mammograms need follow

To bolster infectious disease surveillance, genomics powerhouses team up

focus

fashion

focus

Moonlake's readout produced a cash windfall. Risks remain

Transgender women dream of pregnancy via uterus transplants

How to save PrEP access — and even expand it

The response to Covid

Activists slam private health insurers over coverage restrictions

How a key Senate committee is planning to regulate PBMs

New air purifier tech could be key to improving indoor air quality

FDA sets aggressive timeline for overhauling inspection procedures

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Dana Farber says 6 studies to be retracted and 31 corrected

leisure time

FDA sets aggressive timeline for overhauling inspection procedures

4 missing after record

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

How a key Senate committee is planning to regulate PBMs

Update the Apgar Score to remove skin color

Sophia Smith scores twice for US in in 3

hotspot

entertainment

leisure time

focus